InvestSMART

Global X S&P Biotech ETF (ASX: CURE) - Announcements

Current share price for CURE : $58.600 0.7 (1.18%)+

Global X S&P Biotech ETF (CURE) is an Exchange Traded Fund - commonly known as an ETF. For more details about how ETFs work, feel free to check out our What is an ETF? overview. The Global X S&P Biotech ETF (CURE) seeks to invest in companies that stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Latest company announcements for Global X S&P Biotech ETF (CURE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$38 PDS dated 12 November 2025 12 Nov 2025 5:03PM $59.210 $58.600 fallen by 1.03%
$38 PDS dated 4 November 2025 7 Nov 2025 4:21PM $57.200 $58.600 risen by 2.45%
$38 Global X Units on Issue - October 2025 7 Nov 2025 2:29PM $57.220 $58.600 risen by 2.41%
$38 Global X Units on Issue - September 2025 *Revised* 6 Oct 2025 6:09PM $53.300 $58.600 risen by 9.94%
$38 Global X Units on Issue - September 2025 3 Oct 2025 4:46PM $53.000 $58.600 risen by 10.57%
$38 Annual Financial Report 24 Sep 2025 4:39PM $49.750 $58.600 risen by 17.79%
$38 PDS Update 23 September 2025 23 Sep 2025 2:42PM $50.070 $58.600 risen by 17.04%
$38 PDS dated 22 September 2025 22 Sep 2025 1:34PM $49.220 $58.600 risen by 19.06%
$38 Global X Units on Issue - August 2025 5 Sep 2025 4:39PM $48.510 $58.600 risen by 20.80%
$38 Notice for Change of Contribution and Withdrawal Fees 22 Aug 2025 4:59PM $47.670 $58.600 risen by 22.93%
$38 Global X Units on Issue - July 2025 7 Aug 2025 4:45PM $44.980 $58.600 risen by 30.28%
$38 Global X Units on Issue - June 2025 4 Jul 2025 5:31PM $44.110 $58.600 risen by 32.85%
$38 Global X Final Distribution Announcement - June 2025 2 Jul 2025 7:27PM $43.070 $58.600 risen by 36.06%
$38 Global X Updated Est Distribution Announcement - June 2025 27 Jun 2025 6:07PM $43.510 $58.600 risen by 34.68%
$38 Global X Estimated Distribution Announcement - June 2025 24 Jun 2025 5:28PM $43.850 $58.600 risen by 33.64%
$38 Revised Global X Units on Issue - May 2025 18 Jun 2025 3:15PM $43.135 $58.600 risen by 35.85%
$38 Global X Units on Issue - May 2025 5 Jun 2025 5:19PM $43.100 $58.600 risen by 35.96%
$38 Global X Units on Issue - April 2025 6 May 2025 5:34PM $44.000 $58.600 risen by 33.18%
$38 PDS dated 15 April 2025 30 Apr 2025 1:08PM $43.010 $58.600 risen by 36.25%
$38 Global X Units on Issue - March 2025 4 Apr 2025 4:49PM $42.090 $58.600 risen by 39.23%
$38 Half Year Accounts 14 Mar 2025 4:28PM $46.830 $58.600 risen by 25.13%
$38 Global X Units on Issue - February 2025 6 Mar 2025 5:50PM $47.030 $58.600 risen by 24.60%
$38 PDS dated 12 February 2025 13 Feb 2025 1:40PM $49.190 $58.600 risen by 19.13%
$38 Global X Units on Issue - January 2025 6 Feb 2025 9:36AM $50.440 $58.600 risen by 16.18%
$38 Global X Units on Issue - December 2024 7 Jan 2025 9:15AM $50.320 $58.600 risen by 16.45%

1 - 25 of 121 results

Page 1 of 5

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.